Lundbeckfonden Ventures

Lundbeckfonden Ventures

Lundbeckfonden Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by Lundbeck Foundation

Lundbeckfonden Ventures is an evergreen venture fund that was founded in 2009 and is entirely owned by the Lundbeck Foundation. It invests in life science companies and focuses on projects and companies close to or in clinical development.

Lundbeckfonden Ventures is a venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.

The Lundbeck Foundation

The Lundbeck Foundation is a Danish foundation that was founded in 1954 by Grete Lundbeck and is worth over DKK 60 billion. They award research grants of around DKK 500 million each year to Danish-based, biomedical sciences research, primarily in the field of brain research.

Investments

Lundbeckfonden invests in biotechnology and medical companies worldwide with annual investments of 350 to 400 million Danish kroner.The company invests at early and late venture stage.

Investments include Amplyx Pharmaceuticals, Cydan and Enterome Bioscience and exits include Spero Therapeutics, Acacia Pharma and Ziarco.

Lundbeckfonden Ventures is an evergreen life science venture capital firm in Copenhagen that invests in early and late stage ventures. Established in the autumn of 2009 and wholly owned by Lundbeck Foundation, it offers flexible and long-term investments. It typically invests in Series B, Series A, Series C, and in post-IPO equity. Its portfolio companies include Spero Therapeutics, SANIFIT, Reneo Pharmaceuticals, Aura Biosciences, River Vision Development, Vtesse, Ziarco, Celladon and Asante Solutions.

Since 2009, the company has invested in 31 life science companies in the US and Europe, and have an active portfolio of about 20 companies representing a wide range of therapeutic areas. It invests around DKK 350 to 400 million annually.

Timeline

2009

Founded

Funded Companies

Company
Description
Website
Industry
Location

VarmX is a Netherlands-based biotechnology company manufacturing therapeutic proteins to restore blood clotting in bleeding patients.

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs.

IO Biotech is a company founded in 2014 by Mai-Britt Zocca, PhD, Professor Mads Hald Andersen, Anders Ljungqvist, Professor MD PhD Inge Marie Svane and Professor Per Thor Straten.

Imara is a Cambridge, Massachusetts-based company.

Trevi Therapeutics is a New Haven, Connecticut-based company.

6 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Birgitte Schou

Vice President Finance

Andreas Jurgeit

Partner

Anette Høye

Science Liaison

Anna Jo Dinesen

Student Assitant

Anne-Mare Engel

Head of Talent & Career Programmes

Bertil From

Chief Financial Officer

Britt Wilder

PA to the CEO

Casper Breum

Senior Partner

Casper Breum

Partner

Charlotte Nørkjær

Receptionist

Christian Elling

SVP, Director of Science

Christian Elling

Managing Partner

Christoffer Kluge

Student Assistant

Dorthe Mathiasen

Accountant

Enno Hoffmann-Dose

Head of Strategy

Gitte Grove Stig

Senior Communications Advisor

Håkon Hemme Bro-Jørgensen

Investment Analyst

Hanne Harbo

Receptionist

Helene Mathiasen

Secretary

Henrik Larsen

Science Journalist

Jasper Friese

IT Manager

Jens Karkov Nørgaard

Investment Associate

Jette Brandsen Bundgaard

Associate

Jette Bundgard

Associate

Johan Kördel

Senior Partner

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Imara

Acacia Pharma

Allocure

Amplyx Pharmaceuticals

Asante Solutions

Atox Bio

Aura Biosciences

Biom'up

Bonesupport

Celladon

Cydan Development

DBV Technologies

DYSIS Medical

Dysis Medical Ltd.

Enterome Bioscience

ENTEROME Bioscience

Epitherapeutics

Iconic Therapeutics

Iconic Therapeutics

Imara

Nextim

Psioxus Therapeutics Ltd.

Reneo Pharmaceuticals

Reneo Pharmaceuticals

River Vision LLC.

Page 1 of 2

News

Title
Author
Date
Publisher
Description
Christine Hall
May 19, 2020
Crunchbase News
Biotech company Amplyx Pharmaceuticals increases its Series C to more than $90 million, aimed at advancing two therapies toward clinical development.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.